Marker sequences for gynaecological malignoma and use of same

摘要

Device comprises one or more different marker sequences consisting of a protein with a sequence of SEQ ID NOs: 979-1467 and/or its partial sequences and/or encoded by a sequence of SEQ ID NOs: 1-489, SEQ ID NOs: 490-978 and/or partial sequences of SEQ ID NOs. 1-978 on a carrier, where the above sequences are not defined. Independent claims are included for: (1) an assay or a protein biochip comprising the device; (2) a diagnostic (test kit) for the early detection and/or diagnosis of gynecological malignancy, prognosis and/or predicting the risk of metastasis in gynecological malignancy and the treatment monitoring and/or follow-up of gynecological malignancy comprising the device or an assay or a protein biochip and optionally further additives and auxiliaries; (3) early detection and diagnosis of gynecologic malignancy comprising applying the marker sequences on the carrier, followed by contacting with body fluid or tissue extract of a patient and detecting the interaction of body fluid or tissue extract with the marker sequences; (4) stratifying, preferably for risk stratification or therapy control of a patient with gynecological malignancy comprising determining the autoantibody profile of the patient using the marker sequences and optionally monitoring; (5) a target for the treatment and therapy of gynecological malignancy comprising the proteins; (6) identifying marker sequences for gynecological malignancy comprising providing the marker sequences on an array, identifying of marker sequence candidates for gynecological malignancy marker by comparative analysis of signals by contacting the marker sequences with body fluid or tissue extract of a patient with gynecological malignancy and body fluid or tissue extract of a patient without gynecological malignancy, characterizing the marker sequence candidates for gynecological malignancy using the protein biochip and selecting the marker sequence of candidates for gynecologic malignancy, which provide a different signal in patients with gynecological malignancies and patients without gynecological malignancy (marker sequences for gynecological malignancy); and (7) identifying and/or characterizing a substance (active ingredient) for gynecological malignancy comprising contacting the marker sequences consisting of the proteins and/or proteins encoded by a nucleic acid sequence with at least one substance to be examined and determining the binding. ACTIVITY : ACTIVITY -Cytostatic. MECHANISM OF ACTION : None given.